Hims & Hers (HIMS) Stock Could Be A Bargain After The Pullback

Hims & Hers Health stock has more than tripled over the past three years, yet its recent pullback and mixed valuation score leave the current price debate finely balanced rather than obvious in either direction.

• The share price has gained about 336% over three years, which keeps long term holders well ahead even after the recent slump.
• Expansion into markets such as Australia can support long run revenue ambitions, while regulatory and legal actions around privacy and drug practices may weigh on how investors price the business.
• The company carries a mixed valuation read, with a value score of 4, which points to neither a clear bargain nor an obviously expensive stock on the wider checks.

The issue now is whether Hims & Hers Health’s sharp multi year gain and current legal and regulatory backdrop leave enough valuation support at today’s level.

Capitalize on Hims & Hers Health’s sharp swing in sentiment by lining up potential alternatives across 11 resilient stocks with low risk scores before the next bout of volatility reshuffles the opportunity set.

Is Hims & Hers Health Still Cheap on Sales?

P/S is a useful lens for Hims & Hers Health because the business is still valued heavily on revenue scale rather than accounting earnings. The stock trades on a P/S ratio of 2.5x, which is above the broader healthcare industry average of 1.4x but sits below a peer group average of 4.5x.

The valuation model that blends factors like growth profile, margins, size and risk points to a fair P/S ratio of about 5.0x for Hims & Hers Health. That level is meaningfully higher than the current 2.5x. This suggests the market price does not fully reflect what this framework indicates the sales base might support, even with the current legal and regulatory noise in the background. Because the recent FDA and legal headlines focus heavily on practices rather than the absolute level of revenue, the gap between current and fair P/S multiples remains the key signal here.

On the P/S yardstick, Hims & Hers Health appears undervalued relative to what this model implies its revenue stream could justify.

See what the numbers say about this price — find out in our valuation breakdown.

The Hims & Hers Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the P/S puzzle leaves off for Hims & Hers Health by explaining which paths for growth, margins and earnings would need to occur for the current share price to appear either too low or too high. Each scenario links a potential value to a clear storyline about catalysts and risks, so you can track over time which version of Hims & Hers Health's future seems closest to reality on the Community page.

Community views on Hims & Hers Health could hardly be further apart, with one camp focused on a multi product healthcare platform and the other on rising regulatory and margin risks.

Bull case: 84% undervalued

"The long-term goal is becoming increasingly clear: the front door for customers, the delivery channel, the platform and eventually a healthcare ecosystem..."

Read the full Bull Case to see why Hims & Hers Health could be undervalued

Bear case: 19% overvalued

"Regulatory and consumer pressures threaten user growth, pricing power, and margins, especially amid expanding generic competition and industry shifts toward price transparency..."

Read the full Bear Case to see why Hims & Hers Health could be overvalued

Do you think there's more to the story for Hims & Hers Health? Head over to our Community to see what others are saying!

The Bottom Line

Hims & Hers Health screens as undervalued on a revenue multiple, yet broader checks paint a more mixed picture rather than a straightforward bargain. The current P/S discount only helps if the business sustains its commercial momentum without regulatory or legal costs eroding the economics. Everything now hinges on a single question. Does the current scrutiny around privacy and drug practices prove temporary noise, or is it a lasting overhang that keeps the multiple capped even if sales keep growing?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com